AI drug-discovery company Ten63 Therapeutics Inc announced on Wednesday the launch of BEYOND-Alpha, an early adopter programme through which pharmaceutical companies will work with Ten63 to apply its BEYOND computational drug design platform.
Japan-based Chugai Pharmaceutical Co Ltd is the first pharmaceutical company to participate in the BEYOND-Alpha programme.
Ten63 says that through BEYOND-Alpha, a limited number of early participants will work with the company to apply BEYOND across challenging targets. BEYOND-Alpha is designed to allow Ten63's computational design infrastructure to operate across multiple drug discovery programmes in parallel.
As part of BEYOND-Alpha, Ten63 will apply its proprietary computational drug design platform, BEYOND, to Chugai-nominated targets that present challenges for conventional small-molecule discovery approaches. Ten63 will generate and rank molecular structures designed against each target. Chugai will have the right to negotiate terms for the further research, development, and commercialisation of molecules including the structures generated by Ten63 against each target, subject to the execution of a separate definitive agreement.
Chugai's participation in BEYOND-Alpha expands on the investment from Chugai Venture Fund, the corporate venture arm of Chugai, in Ten63's strategic financing announced in February 2026.
BEYOND is Ten63's computational drug design platform for generative chemistry, built to maintain accuracy across low-data and challenging targets. According to the company, in recent prospective studies across diverse protein targets, BEYOND-generated designs achieved SPR-confirmed hit rates ranging from 11-75%, including against targets for which leading co-folding methods had previously produced few or no confirmed binders.
Ten63 Therapeutics launches BEYOND-Alpha early adopter programme
Eloxx Pharmaceuticals publishes Phase 2a exaluren data in nonsense mutation Alport syndrome
Bristol Myers Squibb reports first Phase 3 data for KarXT in Alzheimer's-related psychosis
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Dicot Pharma initiates phase 2b clinical study of erectile dysfunction drug candidate
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial
Rakuten Medical launches Phase 1 first-in-human trial of PD-L1-targeted RM-0256 photoimmunotherapy
BioArctic and Eisai report positive five-year data for Leqembi in early Alzheimer's disease
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
AstraZeneca rare disease unit secures US and EU approvals for Klygefa in myasthenia gravis
Genentech secures first FDA approval for primary membranous nephropathy treatment